Targeted radiotherapy using agents tagged with α-emitting radionuclides is gaining traction with several clinical trials already undertaken or ongoing, and others in the advanced planning stage. The most commonly used α-emitting radionuclides are 213Bi, 211At, 223Ra and 225Ac. While each one of these has pros and cons, it can be argued that 211At probably is the most versatile based on its half life, decay scheme and chemistry. On the other hand, for targeting bone metastases, 223Ra is the ideal radionuclide because simple cationic radium can be used for this purpose. In this review, we will discuss the recent developments taken place in the application of 211At-labeled radiopharmaceuticals and give an overview of the current status of 223Ra for targeted α-particle radiotherapy.
Keywords: Alpha-particle radiotherapy, astatine-211, radium-223, alpha-emitting radionuclides, [211At]Astatide, sodium iodide symporter, Meta-[211At]astatobenzylguanidine, MABG, Peptides and Non-Antibody Proteins, Monoclonal Antibodies, 223RADIUM AGENTS